<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04814212</url>
  </required_header>
  <id_info>
    <org_study_id>DEBATE</org_study_id>
    <nct_id>NCT04814212</nct_id>
  </id_info>
  <brief_title>Drug-Coated Balloon in Anticoagulated and Bleeding Risk Patients Undergoing PCI</brief_title>
  <acronym>DEBATE</acronym>
  <official_title>Drug-Coated Balloon in Anticoagulated and Bleeding Risk Patients Undergoing PCI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>North Karelia Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Central Hospital of Lapland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kuopio University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Central Finland Hospital District</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>North Karelia Central Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare DCB with DES in stable CAD or ACS patients who are at&#xD;
      high risk of bleeding. Our hypothesis is that the strategy of using DCB and therefore shorter&#xD;
      DAPT regimen is superior to the treatment using DES and longer DAPT in patients at high risk&#xD;
      of bleeding.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Implantation of a drug-eluting stent (DES) has become a standard of percutaneous coronary&#xD;
      intervention (PCI) during the last two decades. However there are still significant drawbacks&#xD;
      in using DES as a permanent coronary implant. Most importantly, bleeding remains a&#xD;
      significant complication of PCI, especially in elderly patients. The number of PCI patients&#xD;
      having OAC:s is already significant, and will grow in the future, as the volume of PCIs in&#xD;
      octogenarians increases, and so does the incidence of atrial fibrillation by age. After&#xD;
      stenting at least one month lasting dual antiplatlet treatment (DAPT) is mandatory, and it&#xD;
      cannot be safely terminated in case of a bleed. The optimal duration of DAPT on patients at&#xD;
      bleeding risk is not known.&#xD;
&#xD;
      Balloon coated with paclitaxel and iopromide (drug-coated balloon, DCB) was originally&#xD;
      developed for the treatment of in-stent restenosis, but later its potential for the treatment&#xD;
      of de-novo coronary artery leasons has become clear in large registry trials. So far, the&#xD;
      randomized controlled studies have shown the non-inferiority of PCI using DCB in comparison&#xD;
      to DES in de novo leasons in small vessels. Also the non-inferiority of PCI using DCB in&#xD;
      comparison to BMS was shown in the DEBUT trial in large vessels on patients at high bleeding&#xD;
      risk. These results need to be confirmed in comparison of DCB to DES as the use of BMS is&#xD;
      diminishing.&#xD;
&#xD;
      Our hypothesis in the DEBATE trial is that DCB and shorter DAPT regimen is superior to the&#xD;
      treatment using DES and longer DAPT duration in the treatment of stable CAD or in ACS (UAP or&#xD;
      NSTEMI) in patients on anticoagulation medication or otherwise on high bleeding risk.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2027</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Randomization to the study groups is done using the Random generator in blocks of 20 without stratification</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The composite of MACE and BARC type 2-5 bleeding episodes</measure>
    <time_frame>12 months</time_frame>
    <description>Major Adverse Cardiac Event = a composite of cardiac death, nonfatal myocardial infarction (MI) and ischemia driven-target lesion revascularization (ID-TLR). BARC = Bleeding academic research consortium. In stable patients, the evidence of ischemia is acquired either by non-invasive testing (for example stress ECG or perfusion imaging) or by pressure wire measurement (FFR) during coronary angiography.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The composite of MACE and BARC2-5 bleedings</measure>
    <time_frame>24 and 36 months</time_frame>
    <description>Major Adverse Cardiac Event = a composite of cardiac death, nonfatal myocardial infarction (MI) and ischemia driven-target lesion revascularization (ID-TLR). BARC = Bleeding academic research consortium. In stable patients, the evidence of ischemia is acquired either by non-invasive testing (for example stress ECG or perfusion imaging) or by pressure wire measurement (FFR) during coronary angiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACE</measure>
    <time_frame>12, 24 and 36 months</time_frame>
    <description>Composite of cardiac death, nonfatal myocardial infarction (MI) and ischemia driven-target lesion revascularization (ID-TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BARC2-5 bleedings</measure>
    <time_frame>12, 24 and 36 months</time_frame>
    <description>BARC = Bleeding academic research consortium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BARC3-5 bleedings</measure>
    <time_frame>12, 24 and 36 months</time_frame>
    <description>BARC = Bleeding academic research consortium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total mortality</measure>
    <time_frame>12, 24 and 36 months</time_frame>
    <description>All-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular mortality</measure>
    <time_frame>12, 24 and 36 months</time_frame>
    <description>Cardiovascular death is defined as death resulting from cardiovascular causes. The following categories may be collected:&#xD;
Death caused by acute MI&#xD;
Death caused by sudden cardiac, including unwitnessed, death&#xD;
Death resulting from heart failure&#xD;
Death caused by stroke&#xD;
Death caused by cardiovascular procedures&#xD;
Death resulting from cardiovascular hemorrhage&#xD;
Death resulting from other cardiovascular cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TVF</measure>
    <time_frame>12, 24 and 36 months</time_frame>
    <description>Target-vessel failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TLR</measure>
    <time_frame>12, 24 and 36 months</time_frame>
    <description>Target-lesion revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TLF</measure>
    <time_frame>12, 24 and 36 months</time_frame>
    <description>Target-lesion failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>12, 24 and 36 months</time_frame>
    <description>Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document will be used (Circulation. 2018;137:2635-2650)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The composite of TVF and BARC2-5 bleedings</measure>
    <time_frame>12, 24 and 36 months</time_frame>
    <description>Target-vessel failure. BARC = Bleeding academic research consortium.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The composite of TLF and BARC2-5 bleedings</measure>
    <time_frame>12, 24 and 36 months</time_frame>
    <description>Target-lesion failure. BARC = Bleeding academic research consortium.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The composite of TLR and BARC2-5 bleedings</measure>
    <time_frame>12, 24 and 36 months</time_frame>
    <description>Target-lesion revascularization. BARC = Bleeding academic research consortium.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute vessel closure as defined by the international consensus criteria for definite/probable stent thrombosis</measure>
    <time_frame>12, 24 and 36 months</time_frame>
    <description>Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document will be used (Circulation. 2018;137:2635-2650)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization for urgent revascularization</measure>
    <time_frame>12, 24 and 36 months</time_frame>
    <description>Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document will be used (Circulation. 2018;137:2635-2650)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke (ischemic or hemorrhagic) or TIA</measure>
    <time_frame>12, 24 and 36 months</time_frame>
    <description>- Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document will be used (Circulation. 2018;137:2635-2650)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">546</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Drug-coated balloon (DCB)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The coronary lesions fulfilling the inclusion criteria and randomized to the DCB group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug-eluting stent (DES)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The coronary lesions fulfilling the inclusion criteria and randomized to the DCB group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Percutaneous coronary intervention using drug-coated balloon</intervention_name>
    <description>SeQuent Please (BBraun) + tailored antithrombotic regimen: 1) Stable patients without OAC: perioperative SAPT (preferably) or perioperative DAPT followed by lifelong SAPT 2) Stable patients with OAC: perioperative SAPT (preferably) or perioperative DAPT 3) ACS patients without OAC: 1-month DAPT followed by lifelong SAPT 4) ACS patients with OAC: perioperative DAPT followed by 1-month SAPT</description>
    <arm_group_label>Drug-coated balloon (DCB)</arm_group_label>
    <other_name>DCB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Percutaneous coronary intervention using drug-eluting stent</intervention_name>
    <description>Biofreedom (Biosensors), Synergy (Boston Scientific), Ultimaster Tansei (Terumo) and Integrity Onyx (Medtronic) + tailored antithrombotic regimen: 1) Stable patients without OAC: 1-month DAPT followed by lifelong SAPT 2) Stable patients with OAC: perioperative DAPT followed by 12 months SAPT (ADP receptor blocker) 3) ACS patients without OAC: 3-month DAPT followed by lifelong SAPT 4) ACS patients with OAC: perioperative DAPT followed by 12 months SAPT (ADP receptor blocker)</description>
    <arm_group_label>Drug-eluting stent (DES)</arm_group_label>
    <other_name>DES</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Informed written consent&#xD;
&#xD;
          -  At least one major or two minor bleeding risk criteria of Academic Research Consortium&#xD;
             (ARC)&#xD;
&#xD;
        Major Criteria&#xD;
&#xD;
          -  Long-term oral anticoagulation&#xD;
&#xD;
          -  Severe or end stage chronic kidney disease (CKD) (estimated glomerular - filtration&#xD;
             rate [eGFR] &lt;30 ml/min)&#xD;
&#xD;
          -  Hemoglobin &lt;110 g/l&#xD;
&#xD;
          -  Spontaneous bleeding requiring hospitalization and transfusion in the past 6 months&#xD;
&#xD;
          -  Moderate to severe baseline thrombocytopenia (platelet count &lt;100 x 10e9/L)&#xD;
&#xD;
          -  Chronic bleeding diathesis&#xD;
&#xD;
          -  Liver cirrhosis with portal hypertension&#xD;
&#xD;
          -  Active cancer in the past 12 months&#xD;
&#xD;
          -  Previous spontaneous ICH (at any time)&#xD;
&#xD;
          -  Previous traumatic ICH within the past 12 months&#xD;
&#xD;
          -  Presence of known brain arteriovenous malformation&#xD;
&#xD;
          -  Moderate to severe ischemic stroke within the past 6 months&#xD;
&#xD;
          -  Nondeferrable major surgery on dual antiplatelet therapy&#xD;
&#xD;
          -  Recent major surgery or trauma within 30 days before PCI&#xD;
&#xD;
        Minor Criteria&#xD;
&#xD;
          -  Age &gt;75 years&#xD;
&#xD;
          -  Moderate CKD (eGFR 30-59 ml/min)&#xD;
&#xD;
          -  Hemoglobin 110-129 g/l for men and 110-119 g/l for women&#xD;
&#xD;
          -  Spontaneous bleeding requiring hospitalization or transfusion within the past 12 -&#xD;
             months not meeting major criterion&#xD;
&#xD;
          -  Long term use of oral nonsteroidal antiinflammatory drugs or steroids&#xD;
&#xD;
          -  Any ischemic stroke at any time not meeting major criterion&#xD;
&#xD;
        Either of the following:&#xD;
&#xD;
          1. Stabile angina or dyspnea and a coronary narrowing causing myocardial ischemia&#xD;
             detected in the angiogram. In stable patients prior PCI, the evidence of ischemia is&#xD;
             needed acquired either by perfusion imaging or by pressure wire measurement (FFR)&#xD;
             during coronary angiography unless the coronary stenosis is &gt; 90% in diameter.&#xD;
&#xD;
          2. ACS (UAP or NSTEMI): symptoms of heart ischemia≥ 20 minutes and ≥ 0,5mm ST-depression&#xD;
             or transient ST-elevation or T-wave inversion at least in two adjacent leads and/or a&#xD;
             high sensitivity troponin (hs-tnt) rise at least one unit above the 99. percentil or&#xD;
             at least 50% rise in hs-tnt between two samples taken 1-3 hours apart.&#xD;
&#xD;
        At least one of the following:&#xD;
&#xD;
          -  ≥1 de novo lesions in native coronary arteries or bypass vein grafts&#xD;
&#xD;
          -  Reference diameter of the vessel is 2.0-5.0mm'&#xD;
&#xD;
          -  Lesion length ≤ 40mm&#xD;
&#xD;
          -  Lesion or lesions are suitable for PCI&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to give written consent&#xD;
&#xD;
          -  STEMI&#xD;
&#xD;
          -  Reference diameter of the vessel is &lt;2.0mm or &gt;5.0 mm&#xD;
&#xD;
          -  Bifurcation lesion requiring the stenting of either of the branches after&#xD;
             predilatation (TIMI&lt;3 or significant recoil &gt;30% in the main epicardial vessel: LAD,&#xD;
             LCX or RCA) after predilatation)&#xD;
&#xD;
          -  Dissection affecting the flow (TIMI&lt;3) or significant recoil (&gt;30% in the main&#xD;
             epicardial vessel: LAD, LCX or RCA) after predilatation&#xD;
&#xD;
          -  in-stent restenosis&#xD;
&#xD;
          -  Chronic total occlusion&#xD;
&#xD;
          -  Life expectancy &lt; 12 months&#xD;
&#xD;
          -  Cardiogenic shock at the arrival to the coronary angiography&#xD;
&#xD;
          -  Uncertainty about neurological recovery e.g. after resuscitation&#xD;
&#xD;
          -  Need for bypass surgery by heart team decision&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tuomas T Rissanen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>North Karelia Central Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tuomas Rissanen, MD, PhD</last_name>
    <phone>+358505998022</phone>
    <email>tuomas.rissanen@siunsote.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alma Toivonen, MD</last_name>
    <email>alma.toivonen@siunsote.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Central Hospital of Central Finland</name>
      <address>
        <city>Jyväskylä</city>
        <state>Keski-Suomi</state>
        <zip>40620</zip>
        <country>Finland</country>
      </address>
    </facility>
    <contact>
      <last_name>Tuukka Joki, MD</last_name>
      <email>tuukka.joki@ksshp.fi</email>
    </contact>
    <investigator>
      <last_name>Tuukka Joki, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jarkko Niva, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central Hospital of Lapland</name>
      <address>
        <city>Rovaniemi</city>
        <state>Lappi</state>
        <zip>96400</zip>
        <country>Finland</country>
      </address>
    </facility>
    <contact>
      <last_name>Annika Olli, MD</last_name>
      <email>annika.olli@lshp.fi</email>
    </contact>
    <investigator>
      <last_name>Annika Olli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Magnus Hagnäs, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hanna Tormilainen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kuopio University Hospital</name>
      <address>
        <city>Kuopio</city>
        <state>Pohjois-Savo</state>
        <zip>70210</zip>
        <country>Finland</country>
      </address>
    </facility>
    <contact>
      <last_name>Jussi Kärkkäinen, MD, PhD</last_name>
      <email>jussi.karkkainen@kuh.fi</email>
    </contact>
    <investigator>
      <last_name>Jussi Kärkkäinen, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hannu Romppainen, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <state>Uusimaa</state>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <contact>
      <last_name>Mikko Minkkinen, MD, PhD</last_name>
      <email>mikko.j.minkkinen@hus.fi</email>
    </contact>
    <investigator>
      <last_name>Mikko Minkkinen, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <state>Varsinais-Suomi</state>
        <zip>20521</zip>
        <country>Finland</country>
      </address>
    </facility>
    <contact>
      <last_name>Tuomas Kiviniemi, MD, PhD</last_name>
      <email>tuomas.kiviniemi@tyks.fi</email>
    </contact>
    <investigator>
      <last_name>Tuomas Kiviniemi, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Karelia Central Hospital</name>
      <address>
        <city>Joensuu</city>
        <zip>80210</zip>
        <country>Finland</country>
      </address>
    </facility>
    <contact>
      <last_name>Tuomas Rissanen, MD, PhD</last_name>
      <email>tuomas.rissanen@siunsote.fi</email>
    </contact>
    <investigator>
      <last_name>Tuomas Rissanen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antti Eranti, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alma Toivonen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 22, 2021</study_first_submitted>
  <study_first_submitted_qc>March 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2021</study_first_posted>
  <last_update_submitted>September 5, 2021</last_update_submitted>
  <last_update_submitted_qc>September 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>North Karelia Central Hospital</investigator_affiliation>
    <investigator_full_name>Tuomas Rissanen</investigator_full_name>
    <investigator_title>Head of Heart Center</investigator_title>
  </responsible_party>
  <keyword>drug-coated balloon</keyword>
  <keyword>drug eluting stent</keyword>
  <keyword>coronary artery disease</keyword>
  <keyword>acute coronary syndrome</keyword>
  <keyword>percutaneous coronary intervention</keyword>
  <keyword>DCB</keyword>
  <keyword>DES</keyword>
  <keyword>drug coated balloon</keyword>
  <keyword>drug-eluting stent</keyword>
  <keyword>drug-eluting balloon</keyword>
  <keyword>high bleeding risk</keyword>
  <keyword>HBR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

